Your browser is no longer supported. Please, upgrade your browser.
Settings
APLS [NASD]
Apellis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.80 Insider Own3.60% Shs Outstand80.65M Perf Week2.75%
Market Cap2.99B Forward P/E- EPS next Y-6.07 Insider Trans-6.28% Shs Float69.52M Perf Month-1.87%
Income-460.30M PEG- EPS next Q-1.71 Inst Own77.00% Short Float9.17% Perf Quarter-47.69%
Sales251.30M P/S11.89 EPS this Y6.30% Inst Trans0.79% Short Ratio3.99 Perf Half Y-27.01%
Book/sh-1.75 P/B- EPS next Y27.30% ROA-56.80% Target Price- Perf Year-3.56%
Cash/sh6.73 P/C4.99 EPS next 5Y33.30% ROE-834.70% 52W Range27.50 - 73.00 Perf YTD-41.31%
Dividend- P/FCF- EPS past 5Y-37.20% ROI-38.00% 52W High-54.01% Beta1.73
Dividend %- Quick Ratio4.10 Sales past 5Y- Gross Margin90.00% 52W Low22.07% ATR2.37
Employees445 Current Ratio4.20 Sales Q/Q- Oper. Margin- RSI (14)36.92 Volatility4.23% 5.24%
OptionableYes Debt/Eq- EPS Q/Q-73.10% Profit Margin- Rel Volume0.60 Prev Close34.63
ShortableYes LT Debt/Eq- EarningsAug 09 AMC Payout- Avg Volume1.60M Price33.57
Recom1.60 SMA200.33% SMA50-27.89% SMA200-33.92% Volume963,007 Change-3.06%
Sep-10-21Reiterated Oppenheimer Outperform $80 → $65
Sep-10-21Reiterated Needham Buy $85 → $70
Sep-10-21Reiterated Credit Suisse Neutral $50 → $38
Sep-10-21Reiterated BMO Capital Markets Outperform $89 → $69
Sep-10-21Downgrade Wedbush Outperform → Neutral $71 → $39
Aug-19-21Upgrade Wedbush Neutral → Outperform
Aug-19-21Initiated Jefferies Buy $74
May-21-21Initiated UBS Buy $82
Apr-16-21Initiated Goldman Buy $130
Nov-19-20Initiated Needham Buy $59
Sep-01-20Initiated Stifel Buy $40
Jul-20-20Initiated ROTH Capital Buy $50
Jun-17-20Initiated BTIG Research Neutral
Apr-01-20Initiated Raymond James Strong Buy $86
Mar-31-20Initiated BMO Capital Markets Outperform $54
Mar-11-20Upgrade Wedbush Underperform → Neutral $29
Jan-07-20Initiated SVB Leerink Mkt Perform $30
Dec-19-19Initiated BofA/Merrill Buy $36
Nov-22-19Initiated Wedbush Underperform
Nov-05-19Initiated Credit Suisse Neutral $33
Oct-18-21 10:20AM  
10:17AM  
Oct-15-21 07:17AM  
Oct-06-21 04:05PM  
Sep-30-21 11:49AM  
Sep-22-21 12:02PM  
Sep-20-21 07:00AM  
Sep-13-21 11:02AM  
Sep-10-21 04:11PM  
03:07PM  
12:49PM  
12:31PM  
11:39AM  
10:58AM  
10:52AM  
10:40AM  
10:21AM  
08:00AM  
06:35AM  
Sep-09-21 04:05PM  
Sep-08-21 11:30AM  
Sep-07-21 04:05PM  
Sep-03-21 04:05PM  
Aug-11-21 08:36AM  
Aug-10-21 03:36PM  
Aug-09-21 05:25PM  
04:01PM  
Aug-06-21 04:05PM  
Aug-02-21 01:51AM  
Jul-29-21 08:33AM  
07:00AM  
Jul-26-21 07:00AM  
Jul-07-21 10:06PM  
04:05PM  
Jul-06-21 07:42AM  
Jul-02-21 09:19AM  
Jun-30-21 04:15PM  
Jun-28-21 08:29AM  
Jun-23-21 07:00AM  
Jun-09-21 07:45AM  
Jun-03-21 07:00AM  
May-26-21 10:10AM  
May-25-21 08:21AM  
07:00AM  
May-20-21 01:37PM  
May-19-21 08:52AM  
May-18-21 09:39AM  
May-17-21 10:12AM  
09:04AM  
05:46AM  
May-14-21 06:25PM  
May-12-21 10:06AM  
May-07-21 04:05PM  
May-04-21 01:22AM  
May-01-21 03:23AM  
Apr-29-21 08:41AM  
Apr-28-21 05:25PM  
04:01PM  
02:30PM  
12:00PM  
Apr-26-21 08:25AM  
Apr-23-21 08:00AM  
Apr-21-21 07:00AM  
Apr-20-21 10:44AM  
Apr-16-21 12:44PM  
Apr-13-21 07:00AM  
Apr-08-21 11:16AM  
Mar-27-21 11:31AM  
Mar-17-21 05:48PM  
Mar-10-21 09:15AM  
Mar-05-21 04:05PM  
05:58AM  
Mar-04-21 04:05PM  
Mar-01-21 11:05PM  
Feb-26-21 10:14AM  
Feb-25-21 05:45PM  
04:01PM  
02:30PM  
Feb-22-21 08:00AM  
Feb-18-21 04:05PM  
Feb-05-21 04:05PM  
Jan-31-21 11:37PM  
Jan-26-21 05:00PM  
Jan-21-21 07:00AM  
Jan-07-21 06:55AM  
Jan-05-21 07:00AM  
Dec-28-20 10:00AM  
Dec-10-20 06:00AM  
Dec-07-20 10:00AM  
Dec-04-20 04:05PM  
Nov-30-20 07:00AM  
Nov-20-20 12:05PM  
Nov-19-20 06:45AM  
Nov-17-20 10:07AM  
Nov-16-20 07:00AM  
Nov-13-20 10:40AM  
Nov-11-20 07:00AM  
Nov-05-20 07:00AM  
Nov-03-20 10:29AM  
05:27AM  
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grossi FedericoCHIEF MEDICAL OFFICEROct 14Sale34.5775025,92865,430Oct 15 04:02 PM
Grossi FedericoCHIEF MEDICAL OFFICEROct 01Sale33.2675024,94566,180Oct 05 04:16 PM
Grossi FedericoCHIEF MEDICAL OFFICERSep 28Option Exercise3.764,00015,04066,930Sep 29 09:48 PM
Dunlop A. SinclairDirectorSep 10Option Exercise14.006,89496,51666,894Sep 13 04:10 PM
Watson David O.General CounselSep 10Option Exercise4.319544,11299,193Sep 13 04:08 PM
Machiels AlecDirectorAug 16Option Exercise2.672,5006,675672,044Aug 17 04:42 PM
Machiels AlecDirectorAug 16Sale56.952,500142,375669,544Aug 17 04:42 PM
Perry Nicole DVice President - AccountingAug 02Option Exercise3.761,0003,7605,847Aug 03 04:23 PM
Grossi FedericoCHIEF MEDICAL OFFICERAug 02Sale63.9925015,99862,930Aug 03 04:26 PM
Perry Nicole DVice President - AccountingAug 02Sale63.991,00063,9904,847Aug 03 04:23 PM
DeLong Mark JeffreySenior Vice PresidentJul 21Option Exercise15.521,00015,52010,490Jul 22 04:24 PM
Francois CedricChief Executive OfficerJul 21Option Exercise4.3114,41062,1071,234,243Jul 22 04:04 PM
DeLong Mark JeffreySenior Vice PresidentJul 21Sale65.001,00065,0009,490Jul 22 04:24 PM
Machiels AlecDirectorJul 15Option Exercise2.672,5006,675672,044Jul 16 06:38 PM
DeLong Mark JeffreySenior Vice PresidentJul 15Option Exercise15.521,00015,52010,490Jul 16 06:40 PM
DeLong Mark JeffreySenior Vice PresidentJul 15Sale62.301,00062,3009,490Jul 16 06:40 PM
Machiels AlecDirectorJul 15Sale62.302,500155,750669,544Jul 16 06:38 PM
Grossi FedericoCHIEF MEDICAL OFFICERJul 14Sale64.6850032,34063,180Jul 15 04:56 PM
Grossi FedericoCHIEF MEDICAL OFFICERJul 08Sale65.6825016,42063,680Jul 09 03:59 PM
Grossi FedericoCHIEF MEDICAL OFFICERJun 28Option Exercise3.769,00033,84063,930Jun 29 04:58 PM
Deschatelets PascalChief Scientific OfficerJun 24Option Exercise2.676,25016,688875,837Jun 25 09:48 PM
Deschatelets PascalChief Scientific OfficerJun 24Sale65.616,250410,062869,587Jun 25 09:48 PM
Watson David O.General CounselJun 21Option Exercise4.314892,10898,239Jun 22 04:02 PM
Machiels AlecDirectorJun 15Option Exercise2.672,5006,675672,044Jun 16 04:33 PM
DeLong Mark JeffreySenior Vice PresidentJun 15Option Exercise15.524,00062,08013,490Jun 16 04:32 PM
Machiels AlecDirectorJun 15Sale64.832,500162,075669,544Jun 16 04:33 PM
DeLong Mark JeffreySenior Vice PresidentJun 15Sale64.964,000259,8309,490Jun 16 04:32 PM
Grossi FedericoCHIEF MEDICAL OFFICERJun 14Sale61.8450030,92054,930Jun 15 04:03 PM
Perry Nicole DVice President - AccountingJun 11Option Exercise3.201,0003,2005,847Jun 15 04:04 PM
Perry Nicole DVice President - AccountingJun 11Sale61.551,00061,5554,847Jun 15 04:04 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERJun 10Sale60.003,417205,02026,651Jun 11 04:07 PM
Sullivan Timothy EugeneChief Financial OfficerJun 08Option Exercise10.0339,880399,99674,141Jun 09 04:06 PM
Perry Nicole DVice President - AccountingJun 01Option Exercise3.761,0003,7605,847Jun 02 04:15 PM
Perry Nicole DVice President - AccountingJun 01Sale56.401,00056,4004,847Jun 02 04:15 PM
Watson David O.General CounselMay 28Option Exercise4.314892,10897,750Jun 01 04:53 PM
Deschatelets PascalChief Scientific OfficerMay 24Option Exercise2.676,25016,688875,837May 25 04:01 PM
Deschatelets PascalChief Scientific OfficerMay 24Sale47.406,250296,250869,587May 25 04:01 PM
Dunlop A. SinclairDirectorMay 20Sale48.105,773277,68131,855May 20 04:53 PM
Dunlop A. SinclairDirectorMay 19Sale50.007,612380,600300,679May 20 04:53 PM
DeLong Mark JeffreySenior Vice PresidentMay 18Option Exercise15.522,00031,04011,490May 19 04:04 PM
DeLong Mark JeffreySenior Vice PresidentMay 18Sale55.002,000110,0009,490May 19 04:04 PM
Dunlop A. SinclairDirectorMay 18Sale52.85149,4887,899,84737,628May 20 04:53 PM
Machiels AlecDirectorMay 14Option Exercise2.672,5006,675672,044May 18 04:05 PM
Grossi FedericoCHIEF MEDICAL OFFICERMay 14Sale45.3950022,69555,430May 18 04:06 PM
Machiels AlecDirectorMay 14Sale45.392,500113,475669,544May 18 04:05 PM
Perry Nicole DVice President - AccountingMay 03Option Exercise3.761,0003,7605,847May 04 04:14 PM
Grossi FedericoCHIEF MEDICAL OFFICERMay 03Sale50.7360030,43855,614May 04 04:11 PM
Perry Nicole DVice President - AccountingMay 03Sale50.731,00050,7304,847May 04 04:14 PM
Perry Nicole DVice President - AccountingApr 30Option Exercise3.761,0003,7605,847May 03 05:40 PM
Perry Nicole DVice President - AccountingApr 30Sale50.001,00050,0004,847May 03 05:40 PM
Deschatelets PascalChief Scientific OfficerApr 23Option Exercise2.676,25016,688871,337Apr 26 06:02 PM
Dunlop A. SinclairDirectorApr 23Option Exercise14.0010,000140,00060,000Apr 26 06:00 PM
Deschatelets PascalChief Scientific OfficerApr 23Sale46.136,250288,312865,087Apr 26 06:02 PM
Watson David O.General CounselApr 22Option Exercise4.314892,10897,261Apr 23 04:02 PM
Machiels AlecDirectorApr 21Option Exercise2.672,5006,675672,044Apr 22 06:17 PM
Machiels AlecDirectorApr 21Sale45.762,500114,400669,544Apr 22 06:17 PM
Dunlop A. SinclairDirectorApr 16Option Exercise14.0050,000700,00050,000Apr 19 07:29 PM
Grossi FedericoCHIEF MEDICAL OFFICERApr 14Sale42.8250021,41056,214Apr 15 05:55 PM
Grossi FedericoCHIEF MEDICAL OFFICERApr 01Sale43.4160026,04656,714Apr 05 05:11 PM
Watson David O.General CounselMar 22Option Exercise4.319784,21596,772Mar 23 04:14 PM
Machiels AlecDirectorMar 15Option Exercise2.672,5006,675672,044Mar 17 04:16 PM
Machiels AlecDirectorMar 15Sale46.772,500116,925669,544Mar 17 04:16 PM
Grossi FedericoCHIEF MEDICAL OFFICERMar 15Sale46.7750023,38557,314Mar 17 04:14 PM
Deschatelets PascalChief Scientific OfficerMar 10Option Exercise2.676,25016,688871,337Mar 11 04:08 PM
Deschatelets PascalChief Scientific OfficerMar 10Sale50.746,250317,125865,087Mar 11 04:08 PM
Grossi FedericoCHIEF MEDICAL OFFICERMar 05Option Exercise3.205,00016,00062,814Mar 08 04:32 PM
Grossi FedericoCHIEF MEDICAL OFFICERMar 05Sale48.625,000243,07557,814Mar 08 04:32 PM
Perry Nicole DVice President - AccountingMar 01Option Exercise3.762,0007,5204,347Mar 03 04:05 PM
Perry Nicole DVice President - AccountingMar 01Sale50.002,000100,0002,347Mar 03 04:05 PM
Grossi FedericoCHIEF MEDICAL OFFICERMar 01Sale48.5860029,14857,814Mar 03 04:03 PM
Machiels AlecDirectorFeb 16Option Exercise2.672,5006,675672,044Feb 17 04:11 PM
Grossi FedericoCHIEF MEDICAL OFFICERFeb 16Sale46.0050023,00058,414Feb 17 04:12 PM
Machiels AlecDirectorFeb 16Sale46.002,500115,000669,544Feb 17 04:11 PM
Perry Nicole DVice President - AccountingFeb 09Option Exercise3.762,0007,5204,500Feb 10 04:37 PM
Perry Nicole DVice President - AccountingFeb 09Sale50.002,000100,0002,500Feb 10 04:37 PM
Grossi FedericoCHIEF MEDICAL OFFICERFeb 01Sale44.0060026,40059,602Feb 02 04:08 PM
Francois CedricChief Executive OfficerJan 27Option Exercise4.0171,777287,4771,184,856Jan 29 04:19 PM
Watson David O.General CounselJan 27Option Exercise4.0143,483174,51986,887Jan 29 04:18 PM
Grossi FedericoCHIEF MEDICAL OFFICERJan 25Option Exercise3.6315,00054,44050,827Jan 26 04:25 PM
Machiels AlecDirectorJan 15Option Exercise2.672,5006,675672,044Jan 19 04:05 PM
Machiels AlecDirectorJan 15Sale53.152,500132,875669,544Jan 19 04:05 PM
Grossi FedericoCHIEF MEDICAL OFFICERJan 14Sale51.994,000207,96035,827Jan 15 04:10 PM
Perry Nicole DVice President - AccountingJan 04Option Exercise3.762,0007,5202,000Jan 05 04:20 PM
Grossi FedericoCHIEF MEDICAL OFFICERJan 04Sale57.2460034,34439,827Jan 05 04:21 PM
Perry Nicole DVice President - AccountingJan 04Sale57.242,000114,4800Jan 05 04:20 PM
Machiels AlecDirectorDec 15Option Exercise2.672,5006,675672,044Dec 16 04:36 PM
Machiels AlecDirectorDec 15Sale52.162,500130,400669,544Dec 16 04:36 PM
Francois CedricChief Executive OfficerDec 15Sale52.165,000260,8001,113,079Dec 16 04:35 PM
Watson David O.General CounselDec 14Option Exercise13.858,398116,31251,802Dec 15 04:03 PM
Dunlop A. SinclairDirectorDec 14Sale54.6725,0001,366,713174,728Dec 15 05:05 PM
Watson David O.General CounselDec 14Sale52.068,398437,19743,404Dec 15 04:03 PM
Watson David O.General CounselDec 11Option Exercise13.859,935137,60053,339Dec 15 04:03 PM
Watson David O.General CounselDec 11Sale50.009,935496,75043,404Dec 15 04:03 PM
SCHEIBLER LUKASCHIEF INNOVATION OFFICERDec 08Option Exercise26.737,482199,99420,595Dec 09 05:34 PM
Dunlop A. SinclairDirectorDec 07Sale50.7118,564941,399199,728Dec 07 06:58 PM
Perry Nicole DVice President - AccountingDec 04Option Exercise3.7618,00067,68018,000Dec 08 07:32 PM
Grossi FedericoCHIEF MEDICAL OFFICERDec 04Option Exercise3.207,25023,20040,427Dec 08 07:21 PM
Dunlop A. SinclairDirectorDec 04Sale50.266,436323,455218,292Dec 07 06:58 PM
Perry Nicole DVice President - AccountingDec 04Sale50.0018,000900,0000Dec 08 07:32 PM
Francois CedricChief Executive OfficerDec 01Option Exercise3.7640,000150,4001,118,079Dec 02 04:31 PM